Subcellular MLH1 protein as first in class biomarker for CDK4/6 response in endocrine resistant ER+/HER2-breast cancer

被引：0
|
作者：
Mazumder, Aloran
Oropeza, Elena
Punturi, Nindo
Haricharan, Svasti
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5129
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5129
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Discovery of CDK4/6 bifunctional degraders for ER+/HER2-breast cancer
    Majeski, Hannah
    Okano, Akinori
    Pasis, Angela
    Carlson, Casey
    Shakya, Arvind
    Huang, Shenlin
    Chourasia, Aparajita Hoskote
    Fung, Leah M.
    Liu, Qiao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2-breast cancer
    Knudsen, Erik S.
    Witkiewicz, Agnieszka K.
    ONCOTARGET, 2016, 7 (43) : 69111 - 69123
  • [3] Predicting sensitivity to CDK4/6 inhibition in ER+/HER2-breast cancer cell lines
    Bathurst, Lauren
    Liao, Linda
    Crozier, Cheryl
    Bayani, Jane
    Bartlett, John
    Spears, Melanie
    CANCER RESEARCH, 2020, 80 (04)
  • [4] Discovery of CDK4/6 bifunctional degraders for ER+/HER2-breast cancer andtriple negative breast cancer
    Majeski, Hannah
    Okano, Akinori
    Pasis, Angela
    Carlson, Casey
    Liu, Qiao
    Shakya, Arvind
    Huang, Shenlin
    Chourasia, Aparajita Hoskote
    Fung, Leah
    CANCER RESEARCH, 2023, 83 (07)
  • [5] CDK4/6 INHIBITION IMPROVES SURVIVAL IN ER+, HER2- BREAST CANCER
    不详
    CANCER DISCOVERY, 2015, 5 (02) : 107 - 107
  • [6] A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2-breast cancer
    Servetto, Alberto
    Napolitano, Fabiana
    Angelis, Carmine De
    Placido, Pietro De
    Giuliano, Mario
    Arpino, Grazia
    Placido, Sabino De
    Bianco, Roberto
    Formisano, Luigi
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157
  • [7] Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2-breast cancer (LEADER).
    Spring, Laura
    Griffin, Colleen
    Isakoff, Steven J.
    Moy, Beverly
    Wander, Seth Andrew
    Shin, Jennifer
    Abraham, Elizabeth
    Habin, Karleen
    Patel, Jaymin M.
    Comander, Amy H.
    Mulvey, Therese Marie
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2-breast cancer (LEADER, part 1)
    Spring, Laura M.
    Scarpetti, Lauren
    Niemierko, Andrzej
    Isakoff, Steven J.
    Moy, Beverly
    Wander, Seth A.
    Smith, Elisabeth
    Abraham, Elizabeth
    Shin, Jennifer
    Patel, Jaymin M.
    Comander, Amy
    Mulvey, Therese
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [9] SIRT3 as a new potential predictive biomarker for response to CDK4/6 inhibition in ER+/HER2-metastatic breast cancer patients
    Manai, Maroua
    Sahraoui, Ghada
    Doghri, Raoudha
    Gerratana, Lorenzo
    D'Amico, Paolo
    Zhang, Youbin
    Donahue, Jeannine
    Shah, Ami
    Reduzzi, Carolina
    Qiang, Wenan
    Cristofanilli, Massimo
    CANCER RESEARCH, 2024, 84 (09)
  • [10] Breast Cancer CDK4/6 Inhibitors in Patients with metastatic HR+/HER2-Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
12345